The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Why oral semaglutide needs an absorption enhancer at all

This is a generated summary. It shows the 9 most-liked posts from a topic of 66, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
MS
m.strand_rphTL3Pharmacist Solution2 May 2025#4

On variability: the between-person spread in exposure for oral semaglutide is wide enough that two people on the same dose can have quite different plasma concentrations. That is inherent to the absorption route.

It reads as pedantry until the day it does not.

7 likes 15mo
FA
f.amankwahTL220 May 2025#7

Dose equivalence between oral and injectable formulations is not a simple conversion and no published factor should be used as one. The two were developed and titrated separately.

It is a small point and it changes the answer, which is an awkward combination.

24 likes 14mo
QZ
q.zhao_qaTL3Quality assurance5 Jun 2025#10
t.wojcik, post #6: Building on post #5 rather than restating it. SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that transiently raises local pH in the stomach and promotes gastric mucosal absorption. Without it, oral bioavailability of semaglutide would be too low for clinically useful dosing. Go to post

Reading rather than answering, but this is the post I would point somebody at.

25 likes in reply to #6 14mo
KB
k.brandl_deTL3Translator · DE20 Jun 2025#13

Building on post #11 rather than restating it.

Oral semaglutide's bioavailability is low and variable, which is why the dose numbers are an order of magnitude different from the injectable. That is a formulation consequence and not a difference in potency.

I would treat the number as indicative rather than as a measurement.

31 likes 13mo
AD
ambient_draftTL3Regular31 Jul 2025#22

This follows post #21 rather than contradicting it.

The thirty-minute wait before eating is not conservatism. Food in the stomach materially reduces absorption of the oral product, and the instruction exists because the pharmacokinetic studies measured how much.

Adding the caveat now so it does not have to be extracted later.

31 likes 12mo
IA
i.aranda_esTL2Translator · ES17 Sep 2025#34
hana.sato, post #2: Nobody has said the unglamorous part of oral semaglutide yet, so: most of the variation is explained by things that are boring to write about and easy to check. Go to post

Coming back to post #30, because the follow-up matters more than the original answer.

Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.

33 likes in reply to #2 10mo
PN
p.novotnyTL2Regular17 Oct 2025#42

PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the drug but the trial was not designed to establish benefit.

If anyone can point at the primary source I would be grateful.

28 likes 9mo
NH
n.hartmannTL212 Nov 2025#49

Nothing to add, except that this is the answer I would give if asked.

29 likes 8mo
VB
v.bruunTL213 Dec 2025#58

Orforglipron is a small molecule, not a peptide. That changes almost everything: no absorption enhancer required, no fasting window, chemical synthesis instead of peptide synthesis, different analytical methods entirely. Data from peptide agonists does not transfer.

The honest answer is that it depends, and here is what it depends on.

30 likes 7mo

Read the full topic (66 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes
The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable. SOUL trial and oral semaglutide — I have the observation and I do not trust my…
TWBTAMDRM+100 104 4.2k 5mo
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold?
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Posting a…
CAMMMLRRM+23 27 4.8k 22mo
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — setting out what I have, and where I think it stops being reliable. Posting a small dataset on PIONEER 6 cardiovascular…
LCDNMNZGH+25 29 22k 1d
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset
Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Something about Oral versus…
BFAFMNCLAI+27 31 17k 25d
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on…
CFMASD 2 17k 6h

Related topics — sharing the tags randomised trial, orforglipron, oral semaglutide

TopicParticipantsRepliesViewsActivity
Hepatic effects of glucagon receptor agonism: the mechanistic worry
Posting this under the heading it deserves: Hepatic effects of glucagon receptor agonism: the mechanistic worry Everything below is what sits behind that. Something about hepatic effects of glucagon receptor…
TOIOOID+51 56 700 22mo
Oral semaglutide bioavailability and its variability between people — a second dataset
Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Oral semaglutide…
COBOKRHMBS+141 154 47k 19mo
Composite endpoints and the component doing the work
Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did. Collecting what is known about composite endpoints in one place, because…
RVIDSSVKFP+3 7 33k 13h
Second pass at: Retatrutide dose escalation in the published trials
Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on Retatrutide…
BRNKISTM+115 125 30k 2y
Open-label extensions: what survives and what does not
Posting this under the heading it deserves: Open-label extensions: what survives and what does not Everything below is what sits behind that. I have spent a fortnight trying to pin open-label extensions down…
PQZILUCMB 4 22k 3mo